Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C-Reference-Cited by-同舟云学术

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C

Published:2013-08 Issue:2 Volume:59 Page:205-212
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Furusyo Norihiro,Ogawa Eiichi,Nakamuta Makoto,Kajiwara Eiji,Nomura Hideyuki,Dohmen Kazufumi,Takahashi Kazuhiro,Satoh Takeaki,Azuma Koichi,Kawano Akira,Tanabe Yuichi,Kotoh Kazuhiro,Shimoda Shinji,Hayashi Jun

Publisher

Elsevier BV

Subject

Hepatology

Reference29 articles.

1. Long-term mortality after transfusion-associated non-A, non-B hepatitis;Seeff;N Engl J Med,1992

2. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective, multicenter study;Ogawa;J Hepatol,2013

3. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

4. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group

5. Ribavirin concentration in the later stages of 48-week pegylated interferon-alfa 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response;Furusyo;J Antimicrob Chemother,2011

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Old age as a risk factor for liver diseases: Modern therapeutic approaches;Experimental Gerontology;2023-12

2. Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication;Journal of Medical Virology;2022-06-11

3. Pharmacological interventions for acute hepatitis C infection;Cochrane Database of Systematic Reviews;2018-12-03

4. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments;Expert Opinion on Pharmacotherapy;2017-11-22

5. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C;Virology Journal;2017-08-24